Hello, everyone. Nice to see you again. Another pleasant day here on the Pharmalot corporate campus, where still more delicious summer breezes can be felt. Nonetheless, we are preparing for a busy day. In fact, here is a reminder that we will hold our firstwebinar today with Arnie Friede, who will discuss the FDA's DDMAC and its jurisdiction. Please join us. Meanwhile, here are some tidbits to help you get started. Have a great day...
Merck Inks Deal To Market Gardasil In China (Reuters)
Lawyer Who Swinded Wyeth Over Fen-Phen Is Suspended (WDAM)
NICE Ordered To Reassess Celgene's Vidaza (PharmaTimes)
Allergan's Botox Nears US Approval For Migraines (Investor's Business Daily)
India's Regulator Tightens Standards For Drug Applications (Business Standard)
Eisai May Sell Skin-Patch Aricept In US Next Year (Bloomberg News)
Teva Plays Down European Pricing Pressure (Reuters)
AstraZeneca's Brilinta May Be Approved If Study Is Done (Bloomberg News)
New Challenges To Teva's Business Model (Seeking Alpha)
1 Comment
Still a win for AZ. They'll get at least five years to do a US study on Brillinta, during which they can pocket a cool $5-6 billion in sales.